Phaseline

Targets › IFNB1

IFNB1 (Interferon beta): drug programs, companies and trials

2 programs from 2 companies in 3 trials: 2 Phase 3, 1 Phase 2; Immunology, Other, Infectious disease; next expected readout Jul 2030.

Type I interferon cytokine that plays a key role in the innate immune response to infection, developing tumors and other inflammatory stimuli. Signals via binding to high-affinity (IFNAR2) and low-affinity (IFNAR1) heterodimeric receptor, activating the canonical Jak-STAT signaling pathway resulting in transcriptional activation or repression of interferon-regulated genes that encode the effectors of the interferon…. (UniProt, P01574)

Open in Phaseline: the race on IFNB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerDazukibart
Interferon beta inhibitor
IFNB1Phase 3Myositis; DermatomyositisJul 2030
Centre Hospitalier Universitaire, Amiensinhaled type I interferon
type I interferon (IFN-β) with antiviral and immunomodulatory properties
IFNB1Phase 2COVID-19–

Conditions

Myositis (1) Dermatomyositis (1) COVID-19 (1)

Modalities

antibody (1), mixed (1)

Companies

Pfizer (1) Centre Hospitalier Universitaire, Amiens (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.